Original paper
Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer
Abstract
Limited data exist regarding the characteristics and survival outcomes of older adults with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors in routine oncology practice.Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 1256 patients aged ≥65 years who were diagnosed with pathologically confirmed stage I to stage IV NSCLC between 2002 and 2015 and initiated nivolumab or...
Paper Details
Title
Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer
Published Date
Jan 14, 2020
Journal
Volume
126
Issue
5
Pages
978 - 985
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History